United KingdomThis research explores the role of TROP2 targeting in understanding therapy-driven changes in cell states within colorectal cancer (CRC). Colorectal cancer is the second leading cause of cancer-related deaths globally, largely due to late detection and limited effectiveness of current treatments. Standard therapies include combinations like FOLFIRI and FOLFOX, but resistance persists, partly due to cellular plasticity. Recent findings highlight that poor-prognosis CRC tumors exhibit low WNT signaling and belong to specific molecular subtypes, such as iCMS3 and PDS3, which are resistant to conventional treatments. Cancer stem cells (CSCs), particularly LGR5-expressing cells, play a crucial role in tumor maintenance, therapy resistance, and metastasis. However, depletion of these cells has shown that other cell populations, such as those expressing fetal-like markers or activating YAP signaling, can rapidly replenish the CSC pool. This suggests new avenues for targeted therapies based on dynamic cell-state transitions.
Bias read (Center): The article focuses on medical research related to cancer biology and treatment strategies. It does not involve political actors, policies, or ideological debates. The content is purely scientific and discusses biological mechanisms and potential therapeutic targets without any political framing or偏
Why these scores (Factual 85 · Objective 80): The article presents detailed scientific background on colorectal cancer and current treatment challenges with references to studies and clinical data. It discusses molecular subtypes and their prognostic significance without overt bias. However, it lacks specific details on the latest research find
